JCR Pharmaceuticals Co., Ltd. (TYO:4552)
Japan · Delayed Price · Currency is JPY 484.00
-18.00 (-3.59%)
Oct 2, 2026, 3:30 PM JST
JCR Pharmaceuticals Ratios and Metrics
Market cap in millions JPY. Fiscal year is April - March.
Millions JPY. Fiscal year is Apr - Mar.
Total Valuation
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 1, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
| 59,062 | 69,288 | 58,963 | 107,204 | 176,306 | 279,312 | |
Market Cap Growth | -23.55% | 17.51% | -45.00% | -39.19% | -36.88% | -36.97% |
Enterprise Value | 103,758 | 106,682 | 76,238 | 112,497 | 181,176 | 266,306 |
Last Close Price | 484.00 | 556.88 | 459.35 | 788.81 | 1273.38 | 2011.12 |
Price Ratios
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 1, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
PE Ratio | 72.26 | 31.81 | - | 19.47 | 46.74 | 19.25 |
Forward PE | 134.15 | 39.18 | 18.68 | 15.47 | 25.97 | 25.23 |
PS Ratio | 1.42 | 1.72 | 1.78 | 2.50 | 5.13 | 5.47 |
PB Ratio | 1.35 | 1.46 | 1.24 | 1.90 | 3.36 | 5.47 |
P/TBV Ratio | 1.45 | 1.56 | 1.33 | 2.04 | 3.63 | 5.83 |
P/FCF Ratio | - | - | - | 13.77 | - | - |
P/OCF Ratio | - | - | - | 11.51 | - | 30.07 |
PEG Ratio | - | 2.72 | 2.72 | 2.72 | 2.72 | 1.84 |
EV Ratios
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 1, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
EV/Sales Ratio | 2.50 | 2.65 | 2.31 | 2.62 | 5.28 | 5.21 |
EV/EBITDA Ratio | 90.96 | 35.70 | - | 10.49 | 25.98 | 12.17 |
EV/EBIT Ratio | - | 247.52 | - | 14.94 | 36.40 | 13.36 |
EV/FCF Ratio | - | - | - | 14.45 | - | - |
Financial Efficiency
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 1, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Debt / Equity Ratio | 1.24 | 1.14 | 0.80 | 0.41 | 0.44 | 0.35 |
Debt / EBITDA Ratio | 40.72 | 18.04 | - | 2.17 | 3.27 | 0.83 |
Debt / FCF Ratio | - | - | - | 2.99 | - | - |
Net Debt / Equity Ratio | 1.01 | 0.84 | 0.52 | 0.08 | 0.18 | -0.25 |
Net Debt / EBITDA Ratio | 33.43 | 13.35 | -8.20 | 0.42 | 1.37 | -0.59 |
Net Debt / FCF Ratio | - | -3.45 | -1.62 | 0.58 | -0.72 | 6.30 |
Asset Turnover | 0.39 | 0.38 | 0.32 | 0.44 | 0.36 | 0.60 |
Inventory Turnover | 0.43 | 0.44 | 0.51 | 0.59 | 0.54 | 0.74 |
Quick Ratio | 0.51 | 0.59 | 0.58 | 1.12 | 0.68 | 1.11 |
Current Ratio | 1.09 | 1.17 | 1.18 | 1.91 | 1.34 | 1.48 |
Return on Equity (ROE) | 1.90% | 4.64% | -8.44% | 10.17% | 7.32% | 32.39% |
Return on Assets (ROA) | -0.60% | 0.25% | -3.87% | 4.78% | 3.24% | 14.58% |
Return on Invested Capital (ROIC) | -0.53% | 0.37% | -9.59% | 9.36% | 6.96% | 43.48% |
Return on Capital Employed (ROCE) | -1.80% | 0.70% | -10.50% | 10.40% | 8.40% | 36.20% |
Yields
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 1, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Earnings Yield | 1.38% | 3.14% | -7.56% | 5.14% | 2.14% | 5.19% |
FCF Yield | -19.58% | -16.69% | -26.07% | 7.26% | -7.46% | -0.73% |
Dividend Yield | 4.13% | 3.59% | 4.35% | 2.54% | 1.57% | 0.99% |
Payout Ratio | - | 112.07% | - | 45.40% | 72.61% | 14.95% |
Buyback Yield / Dilution | 0.84% | 1.47% | 1.25% | -0.45% | -0.51% | -0.06% |
Total Shareholder Return | 4.97% | 5.06% | 5.61% | 2.09% | 1.06% | 0.93% |